Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elad Sharon

Showing results (111-120 of 191) with videos related to

Pageof 20
Sort By:
The Lancet. Haematology|August 28, 2020
Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trialCatherine S Diefenbach, Fangxin Hong, Richard F Ambinder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2023
Children's Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults With Low-Risk B-Cell ALL in First RelapseLaura E Hogan, Patrick A Brown, Lingyun Ji, et al.
Clinical Pharmacology and Therapeutics|February 15, 2023
The Association Between Baseline Hepatic or Renal Function and Clinical Outcomes for Patients With Non-Small Cell Lung Cancer Treated With a PD-1/PD-L1 Blocking Antibody Using Real-World and Trial DataQi Liu, Raina Mathur, Yuan Xu, et al.
Cancer Communications (London, England)|May 22, 2025
A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohortYoung Kwang Chae, Megan Othus, Sandip Pravin Patel, et al.
JCO Oncology Practice|June 23, 2026
Addressing Biases in Analysis of Time of Infusion: NCI/SWOG Trial S1404 Among Participants With High-Risk Resectable Melanoma Who Received Adjuvant Anti-PD-1 TherapyMegan Othus, Thach-Giao Truong, Elad Sharon, et al.
Journal of Gynecologic Oncology|April 17, 2026
A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: vaginal cancer sub cohort resultsYoung Kwang Chae, Josie Czeskleba, Sandip Pravin Patel, et al.
Cytotherapy|February 27, 2022
Need for aligning the definition and reporting of cytokine release syndrome (CRS) in immuno-oncology clinical trialsMark D Stewart, Bruce McCall, Marcelo Pasquini, et al.
The Lancet. Haematology|August 2, 2023
Brentuximab vedotin with AVD for stage II-IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trialPaul G Rubinstein, Page C Moore, Milan Bimali, et al.
Chest|May 29, 2020
Clinical and Genomic Characteristics of Small Cell Lung Cancer in Never Smokers: Results From a Retrospective Multicenter Cohort StudyAnish Thomas, Idrees Mian, Camille Tlemsani, et al.
Medrxiv : the Preprint Server for Health Sciences|June 9, 2020
Repurposing Existing Medications for Coronavirus Disease 2019: Protocol for a Rapid and Living Systematic ReviewBenjamin P Geisler, Lara Zahabi, Adam E Lang, et al.
Pageof 20

Showing results (111-120 of 191) with videos related to

Sort By:
Pageof 20
The Lancet. Haematology|August 28, 2020
Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trialCatherine S Diefenbach, Fangxin Hong, Richard F Ambinder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2023
Children's Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults With Low-Risk B-Cell ALL in First RelapseLaura E Hogan, Patrick A Brown, Lingyun Ji, et al.
Clinical Pharmacology and Therapeutics|February 15, 2023
The Association Between Baseline Hepatic or Renal Function and Clinical Outcomes for Patients With Non-Small Cell Lung Cancer Treated With a PD-1/PD-L1 Blocking Antibody Using Real-World and Trial DataQi Liu, Raina Mathur, Yuan Xu, et al.
Cancer Communications (London, England)|May 22, 2025
A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohortYoung Kwang Chae, Megan Othus, Sandip Pravin Patel, et al.
JCO Oncology Practice|June 23, 2026
Addressing Biases in Analysis of Time of Infusion: NCI/SWOG Trial S1404 Among Participants With High-Risk Resectable Melanoma Who Received Adjuvant Anti-PD-1 TherapyMegan Othus, Thach-Giao Truong, Elad Sharon, et al.
Journal of Gynecologic Oncology|April 17, 2026
A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: vaginal cancer sub cohort resultsYoung Kwang Chae, Josie Czeskleba, Sandip Pravin Patel, et al.
Cytotherapy|February 27, 2022
Need for aligning the definition and reporting of cytokine release syndrome (CRS) in immuno-oncology clinical trialsMark D Stewart, Bruce McCall, Marcelo Pasquini, et al.
The Lancet. Haematology|August 2, 2023
Brentuximab vedotin with AVD for stage II-IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trialPaul G Rubinstein, Page C Moore, Milan Bimali, et al.
Chest|May 29, 2020
Clinical and Genomic Characteristics of Small Cell Lung Cancer in Never Smokers: Results From a Retrospective Multicenter Cohort StudyAnish Thomas, Idrees Mian, Camille Tlemsani, et al.
Medrxiv : the Preprint Server for Health Sciences|June 9, 2020
Repurposing Existing Medications for Coronavirus Disease 2019: Protocol for a Rapid and Living Systematic ReviewBenjamin P Geisler, Lara Zahabi, Adam E Lang, et al.
Pageof 20